We have investigated in detail the molecular mechanisms of action by which the novel anticancer drug T21 inhibits the antiapoptotic protein survivin in vitro as well as in vivo and have validated this protein as a promising therapeutic target for lung cancer treatment. This evidence concerns the gene BIRC5 and lung carcinoma.